Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs

JAMA

Volumn 304, Issue 3, 2010, Pages 313-320

  Holmes, Charles B ^a   Coggin, William ^a   Jamieson, David ^b   Mihm, Heidi ^c   Granich, Reuben ^a,d   Savio, Phillip ^b   Hope, Michael ^c   Ryan, Caroline ^a   Moloney Kitts, Michele ^a   Goosby, Eric P ^a   Dybul, Mark ^a,e,f  

^a Office of the US Global AIDS Coordinator   (United States)

^b Supply Chain Management System   (United States)

^c UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e GEORGETOWN UNIVERSITY LAW CENTER   (United States)

^f George W Bush Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; GENERIC DRUG; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ARTICLE; BUDGET; CLINICAL PRACTICE; COST CONTROL; DRUG COST; DRUG FORMULATION; FOOD AND DRUG ADMINISTRATION; GUYANA; HAITI; HEALTH ECONOMICS; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SOUTH AFRICA; VIET NAM; WORLD HEALTH ORGANIZATION;

EID: 77954696369     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.993     Document Type: Article

References (16)

1. US President's Plan for AIDS Relief. World AIDS Day 2009: latest PEPFAR results. http://www.pepfar.gov/documents/organization/133033.pdf. Accessed April 23, 2010.
2. US Food and Drug Administration. President's emergency plan for AIDS relief: approved and tentatively approved antiretrovirals in association with the president's emergency plan. http://www.fda.gov/InternationalPrograms/ FDABeyondOurBordersForeignOffices/AsiaandAfrica/ucm119231.htm. Accessed April 24, 2010.
3. World Health Organization. WHO-health systems and services: prequalification of medicines prequalification programme. http://apps.who.int/ prequal/. Accessed April 23, 2010.
4. Supply Chain Management System. About us. http://www.scms.pfscm.org/scms/ about. Accessed April 23, 2010.
5. US President's Plan for AIDS Relief. Report to Congress by the US global AIDS coordinator on the use of generic drugs in the president's emergency plan for AIDS relief: May 2008. http://www.pepfar.gov/documents/organization/105842. pdf. Accessed June 30, 2010.
6. Agresti A, Coull BA. Approximate is better than 'exact' for interval estimation of binomial proportions. Am Stat. 1998;52:119-126. doi:10.2307/2685469.
7. MSF Campaign for Access to Essential Medicines. Untangling the web of antiretroviral price reductions. reports from 2005-2008. http://www.msfaccess. org/resources/key-publications/: Accessed April 24, 2010.
8. Ford N, Gray A, Venter WDF. Tough choices: tenofovir, tenders and treatment. S Afr J HIV. 2008; 9(1):8-10. http://www.msfaccess.org/fileadmin/ user-upload/diseases/hiv-aids/SAJHIV2008%20TDF.pdf. Accessed June 28, 2010.
9. El-Khatib Z, Richter M. (ARV-) Free State? The moratorium's threat to patients' adherence and the development of drug-resistant HIV. S Afr Med J. 2009; 99(6):412-414.
10. Husain M, Lahiri S, Tomar S, Parmar VS, Datta D. Biocatalytic acylation of Efavirenz intermediate: Unexpected novel product formation. Indian J Chem. 2009;48B(8):1174-1177. doi: 10.1002/chin.201001179.
11. World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents: November 2009. http://www.who.int/hiv/pub/ arv/rapid-advice-art.pdf. Accessed January 5, 2010.
12. Ministry of Health Zambia. Antiretroviral therapy for chronic HIV infection in adults and adolescents. National HIV/WIDS/STI/TB Council Web site. http://www.nac.org.zm/attachments/063-new-art-protocols-may-2007.pdf. Accessed June 28, 2010.
13. Rosen S, Long L, Fox M, Sanne I. Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa. J Acquir Immune Defic Syndr. 2008;48(3):334-344.
14. Bender MA, Kumarasamy N, Mayer KH, et al. Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. Clin Infect Dis. 2010;50(3):416-425.
15. Bermudez J, 't Hoen E. The UNITAID patent pool initiative: bringing patents together for the common good. Open AIDS J. 2010;4:37-40.
16. Martinson N, Mohapi L, Bakos D, Gray G, McIntyre JA, Holmes CB. Costs of providing care for HIV-infected adults in an urban HIV clinic in Soweto, South Africa. J Acquir Immune Defic Syndr. 2009;50 (3):327-330.